Diffusion Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) is an innovative biopharmaceutical Company focused on the treatment of acute shortage of oxygen. Moreover, the lead product candidate is not commercialized yet.

Investment Highlights – Diffusion Pharmaceuticals Inc – Hold at USD 0.79

• The Company had completed Phase 1b study for the leading drug candidate trans sodium crocetinate (TSC) related to the treatment of Covid-19 patients, and the results were encouraging.
• DFFN had sufficient cash to fund three short-term Oxygenation Trials in the United States during 2021.
• The Company does not have any long-term debt on the balance sheet.
• From a technical standpoint, 20-day EMA (USD 0.74) supports the upside potential in the stock price.

Key Risks

• The consensus forecast indicated that the Company would report losses for the next four years.
• Changes in government policies and regulations could affect the overall business of the Company.
• The Company is in the development stage and has not reported any revenue yet.

Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 10 May 2021)

(Source: Company result)

• The Company had widened the net loss from negative USD 2.56 million during Q1 FY20 to negative USD 4.64 million for Q1 FY21.
• The Company’s TCOM and COVID trials resulted in the growth of R&D expenses to USD 2.92 million for Q1 FY21.
• DFFN had cash & cash equivalents of USD 46.60 million as of 31 March 2021, while it had USD 18.5 million as of 31 December 2020.

One Year Share Price Chart

 (Analysis done by Kalkine Group)

Conclusion

The Company had strengthened the balance sheet by completing a fund-raising activity of USD 34.5 million in February 2021. Moreover, DFFN believed that it would be able to fund the operations till 2023 with existing cash & cash equivalents as of 31 March 2021. Furthermore, the Company had managed to complete several key milestones during the first quarter of 2021. The Company anticipates the completion of the DLCO Trial and Induced Hypoxia Trial during H2 FY21. The stock made a 52-week low and high of USD 0.595 and USD 1.850, respectively.

Based on the impressive development pipeline and adequate liquidity to fund operations till 2023, we have given a "Hold" stance on Diffusion Pharmaceuticals Inc at the current market price of USD 0.79 (as of 24 June 2021 at 09:38 AM ET), while we will suggest fresh buying once we identify further growth catalysts for the Company.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.